MA27185A1 - Amides substitues actifs au niveau du recepteur de cannabinoides-1 - Google Patents
Amides substitues actifs au niveau du recepteur de cannabinoides-1Info
- Publication number
- MA27185A1 MA27185A1 MA27851A MA27851A MA27185A1 MA 27185 A1 MA27185 A1 MA 27185A1 MA 27851 A MA27851 A MA 27851A MA 27851 A MA27851 A MA 27851A MA 27185 A1 MA27185 A1 MA 27185A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- receptor
- useful
- compounds
- substituted amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Structural Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
AMIDES SUBSTITUÉS Des composés de formule structurale (I) sont des antagonistes et/ou agonistes inverses du récepteur de cannabinoïde-1 (CB1) et sont utiles dans le traitement, la prévention et la suppression de maladies médiées par le récepteur CB1. Les composés de la présente invention sont utiles comme médicaments à action centrale dans le traitement de la psychose, de déficits de mémoire, de toubles cognitifs, de la migraine, de neuropathies, d'affections neuro-inflammatoires y compris la sclérose en plaques, le syndrome de Guillain-Barre et les suites de l'encéphalite virale, d'accidents vasculaires cérébraux, de traumatismes de la tête, d'angoisses sévères, de stress, d'épilepsie, de la maladie de Parkinson, de troubles du mouvement et de la schizophrénie. Les composés sont également utiles pour le traitement de troubles dus à l'abus de substances, ainsi que dans le traitement de l'asthme, de la constipation, de la pseudo-obstruction intestinale chronique et de la cirrhose du foie.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42841502P | 2002-11-22 | 2002-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27185A1 true MA27185A1 (fr) | 2005-01-03 |
Family
ID=32393400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27851A MA27185A1 (fr) | 2002-11-22 | 2004-09-10 | Amides substitues actifs au niveau du recepteur de cannabinoides-1 |
Country Status (25)
Country | Link |
---|---|
KR (1) | KR100748380B1 (fr) |
CN (1) | CN1639112A (fr) |
AR (1) | AR038948A1 (fr) |
AU (1) | AU2003218005A1 (fr) |
BR (1) | BR0308349A (fr) |
CR (1) | CR7432A (fr) |
DO (1) | DOP2003000609A (fr) |
EA (1) | EA007747B1 (fr) |
EC (1) | ECSP045289A (fr) |
GE (1) | GEP20074208B (fr) |
HR (1) | HRP20040823A2 (fr) |
IL (1) | IL163824A0 (fr) |
IS (1) | IS7411A (fr) |
JO (1) | JO2482B1 (fr) |
MA (1) | MA27185A1 (fr) |
MX (1) | MXPA04008748A (fr) |
MY (1) | MY134457A (fr) |
NO (1) | NO20043803L (fr) |
PE (1) | PE20040599A1 (fr) |
PL (1) | PL200328B1 (fr) |
RS (1) | RS79104A (fr) |
TN (1) | TNSN04176A1 (fr) |
TW (1) | TW200408620A (fr) |
UA (1) | UA76590C2 (fr) |
WO (1) | WO2004048317A1 (fr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2478183C (fr) | 2002-03-12 | 2010-02-16 | Merck & Co. Inc. | Amides substitues |
AU2003257145B2 (en) | 2002-08-02 | 2008-11-13 | Merck Sharp & Dohme Corp. | Substituted furo (2,3-b) pyridine derivatives |
EP1575901B1 (fr) | 2002-12-19 | 2012-10-10 | Merck Sharp & Dohme Corp. | Amides substitues |
WO2005009479A1 (fr) * | 2003-06-30 | 2005-02-03 | Merck & Co., Inc. | Modulateurs radiomarques du recepteur de cannabinoide-1 |
JP2007510647A (ja) * | 2003-10-30 | 2007-04-26 | メルク エンド カムパニー インコーポレーテッド | カンナビノイド受容体調節剤としてのアラルキルアミン類 |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
US7629470B2 (en) | 2004-07-08 | 2009-12-08 | Merck & Co., Inc. | Formation of tetra-substituted enamides and stereoselective reduction thereof |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
WO2006035759A1 (fr) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | Médicament pour le traitement de maladies respiratoires |
WO2006035760A1 (fr) * | 2004-09-27 | 2006-04-06 | Santen Pharmaceutical Co., Ltd. | Médicament pour le traitement de maladies de peau |
WO2006043518A1 (fr) * | 2004-10-18 | 2006-04-27 | Santen Pharmaceutical Co., Ltd. | Médicament pour le traitement de maladies neurologiques |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
CN101426500A (zh) * | 2005-05-02 | 2009-05-06 | 默克公司 | 治疗糖尿病和肥胖症的二肽基肽酶iv抑制剂和cb1受体拮抗剂的药物组合物 |
CN101277960A (zh) | 2005-09-29 | 2008-10-01 | 默克公司 | 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物 |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
ES2402581T3 (es) | 2006-02-23 | 2013-05-06 | Pfizer Limited | Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4 |
WO2008017381A1 (fr) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation |
US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
JP2010509392A (ja) | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用 |
CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
EP2145884B1 (fr) | 2007-04-02 | 2014-08-06 | Msd K.K. | Dérivé d'indoledione |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010015972A1 (fr) | 2008-08-06 | 2010-02-11 | Pfizer Limited | Composés diazépines et diazocanes en tant qu'agonistes de mc4 |
JP5635991B2 (ja) | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | イソニコチンアミドオレキシン受容体アンタゴニスト |
US8759539B2 (en) | 2008-11-17 | 2014-06-24 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
CA2768577A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
US8785634B2 (en) | 2010-04-26 | 2014-07-22 | Merck Sharp & Dohme Corp | Spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (fr) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Inhibiteurs inédits de la prolylcarboxypeptidase |
EP2579873A4 (fr) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | Nouveaux inhibiteurs de prolylcarboxypeptidase |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120054A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683702B1 (fr) | 2011-03-08 | 2014-12-24 | Sanofi | Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
WO2020167706A1 (fr) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine |
US20230018413A1 (en) | 2019-08-08 | 2023-01-19 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
EP4200295A1 (fr) | 2020-08-18 | 2023-06-28 | Merck Sharp & Dohme LLC | Agonistes du récepteur de l'orexine de type bicycloheptane pyrrolidine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001516361A (ja) * | 1997-03-18 | 2001-09-25 | スミスクライン・ビーチャム・コーポレイション | 新規カンナビノイド受容体作動薬 |
GEP20053710B (en) * | 2001-02-28 | 2005-12-26 | Merck & Co Inc | Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists |
-
2003
- 2003-02-11 MY MYPI20030464A patent/MY134457A/en unknown
- 2003-02-18 TW TW092103282A patent/TW200408620A/zh unknown
- 2003-03-03 JO JO200320A patent/JO2482B1/en active
- 2003-03-07 EA EA200401066A patent/EA007747B1/ru not_active IP Right Cessation
- 2003-03-07 WO PCT/US2003/007039 patent/WO2004048317A1/fr not_active Application Discontinuation
- 2003-03-07 MX MXPA04008748A patent/MXPA04008748A/es active IP Right Grant
- 2003-03-07 GE GEAP8404A patent/GEP20074208B/en unknown
- 2003-03-07 KR KR1020047014299A patent/KR100748380B1/ko not_active IP Right Cessation
- 2003-03-07 PL PL373656A patent/PL200328B1/pl not_active IP Right Cessation
- 2003-03-07 BR BR0308349-7A patent/BR0308349A/pt not_active IP Right Cessation
- 2003-03-07 PE PE2003000230A patent/PE20040599A1/es not_active Application Discontinuation
- 2003-03-07 AU AU2003218005A patent/AU2003218005A1/en not_active Abandoned
- 2003-03-07 IL IL16382403A patent/IL163824A0/xx unknown
- 2003-03-07 CN CNA03805678XA patent/CN1639112A/zh active Pending
- 2003-03-07 RS YUP-791/04A patent/RS79104A/sr unknown
- 2003-03-12 AR ARP030100857A patent/AR038948A1/es unknown
- 2003-03-12 DO DO2003000609A patent/DOP2003000609A/es unknown
- 2003-07-03 UA UA20040907424A patent/UA76590C2/uk unknown
-
2004
- 2004-08-19 IS IS7411A patent/IS7411A/is unknown
- 2004-08-24 CR CR7432A patent/CR7432A/es unknown
- 2004-09-10 TN TNP2004000176A patent/TNSN04176A1/en unknown
- 2004-09-10 EC EC2004005289A patent/ECSP045289A/es unknown
- 2004-09-10 MA MA27851A patent/MA27185A1/fr unknown
- 2004-09-10 HR HR20040823A patent/HRP20040823A2/hr not_active Application Discontinuation
- 2004-09-10 NO NO20043803A patent/NO20043803L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2003218005A1 (en) | 2004-06-18 |
EA200401066A1 (ru) | 2005-04-28 |
WO2004048317A1 (fr) | 2004-06-10 |
BR0308349A (pt) | 2005-01-25 |
NO20043803L (no) | 2005-05-24 |
GEP20074208B (en) | 2007-10-10 |
RS79104A (en) | 2007-02-05 |
EA007747B1 (ru) | 2006-12-29 |
MY134457A (en) | 2007-12-31 |
KR100748380B1 (ko) | 2007-08-10 |
TW200408620A (en) | 2004-06-01 |
PE20040599A1 (es) | 2004-09-08 |
PL373656A1 (en) | 2005-09-05 |
CN1639112A (zh) | 2005-07-13 |
AR038948A1 (es) | 2005-02-02 |
DOP2003000609A (es) | 2004-06-15 |
PL200328B1 (pl) | 2008-12-31 |
ECSP045289A (es) | 2004-10-26 |
IL163824A0 (en) | 2005-12-18 |
KR20050083563A (ko) | 2005-08-26 |
TNSN04176A1 (en) | 2007-03-12 |
MXPA04008748A (es) | 2004-12-06 |
UA76590C2 (en) | 2006-08-15 |
CR7432A (es) | 2005-10-05 |
JO2482B1 (en) | 2009-01-20 |
IS7411A (is) | 2004-08-19 |
HRP20040823A2 (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27185A1 (fr) | Amides substitues actifs au niveau du recepteur de cannabinoides-1 | |
MA27847A1 (fr) | Derives d'azetidine substituee avec 3-alkyle et 3-alcenyle. | |
DE60316829D1 (de) | Substituierte furoä2,3-büpyridin derivate | |
WO2003077847A3 (fr) | Amides substitues | |
WO2003082190A3 (fr) | Amides spirocycliques en tant que modulateurs du recepteur cannabinoide | |
WO2003063781A3 (fr) | Imidazoles substitues en tant que modulateurs du recepteur cannabinoide | |
PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
WO2004058145A3 (fr) | Amides substitues | |
WO2003086288A3 (fr) | Amides bicycliques | |
ATE452890T1 (de) | Substituierte naphthyridinonderivate | |
WO2004029204A3 (fr) | Pyrimidines substituees | |
WO2009063215A2 (fr) | Utilisation de composés antagonistes de crth2 | |
WO2003007887A3 (fr) | Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides | |
MA30086B1 (fr) | Derives de 3-alkylazetidine a substituants heterocycliques. | |
WO2003082191A3 (fr) | 2,3-diphenyl-pyridines substituees | |
WO2005027837A3 (fr) | Sulfonamides substitues | |
WO2009063202A2 (fr) | Utilisation de composés antagonistes de crth2 | |
US20110124683A1 (en) | Use of CRTH2 Antagonist Compounds | |
PL1735278T3 (pl) | Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne | |
CA2503718A1 (fr) | Traitement pharmacologique de l'apnee du sommeil | |
NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister | |
FR2856596B1 (fr) | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. | |
BR0307504A (pt) | Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal | |
CA2522323A1 (fr) | Derives de 3-azabicyclo[3.2.1]octane comme ligands de recepteurs opioides | |
CN102276523B (zh) | 取代的吡啶衍生物 |